Gilead Sciences Wins "Science's Oscar"

Gilead Sciences Chairman John C. Martin has been recognized with the 2019 American National Academy of Sciences Award for Service to the Community in recognition of his contributions to the development of antiviral medicines used in the treatment of HIV/AIDS, Hepatitis C, Hepatitis B, cytomegalovirus and influenza. Through his work, Martin has enriched the lives of millions of people worldwide and is recognized for his dedication to ensuring that all humanity, regardless of economic income level, benefits from these treatments. Martin, who trained in organic chemistry, focused on using chemistry as a tool to discover and develop potent antiviral drugs. His first major breakthrough came in 1989 with FDA approval of the first treatment for cytomegalovirus (CMV) retinitis in HIV patients. Martin's approach involved the development of biologically inactive compounds called prodrugs that can cross cell membranes and be metabolized into active drugs. This research paved the way for prodrugs that revolutionized the treatment of HIV/AIDS-related diseases and infections. Martin's work continued at Gilead Sciences, where he not only aimed to develop a new paradigm for pharmaceutical pricing and intellectual property, but also directed the company toward creating life-saving medicines including improved new combination treatments for influenza, HIV/AIDS, Hepatitis B and Hepatitis C. Today, more than 15 million people living with HIV, Hepatitis B and/or Hepatitis C worldwide continue their treatment with Gilead Sciences medicines, while more than 60% of HIV treatment patients are covered under the not-for-profit drug access program initiated by Martin. This program is regarded as Martin's contribution to the sustainability of human life.